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We examined the effects of subinhibitory concentrations of ciprofloxacin, tobramycin, and ceftazidime on
Pseudomonas aeruginosa exoenzyme expression in vitro and in vivo. Exotoxin A, exoenzyme S, phospholipase
C, elastase, and total protease activities were suppressed by antibiotics at concentrations as low as 1/20 of the
MIC over a 24-h period in broth. Continuous 10-day exposure of P. aeruginosa DG1 broth cultures to antibiotic
levels equal to 1/10 of the MIC reduced exoenzyme S activity in all treatment groups. Elastase activity was
reduced only by ciprofloxacin and tobramycin treatment. This suppressive effect of the antibiotics persisted
throughout the 10 days and was not influenced by the increase in MIC of ciprofloxacin detected during the
course of the experiment. Rats chronically infected with P. aeruginosa were treated with subinhibitory doses
of antibiotics and compared with untreated controls. Bacterial numbers in lung homogenates from each of the
four study groups were identical. However, the lungs from antibiotic-treated rats had significantly less
histological damage than those from control rats (P < 0.001). The protective effect was greatest for
ciprofloxacin and tobramycin. Further, P. aeruginosa isolates from ciprofloxacin- and tobramycin-treated rats
demonstrated significantly less exoentyme S and elastase activity than isolates from untreated rats (P < 0.001).
Isolates from ceftazidime-treated lungs expressed less exoenzyme S activity (P < 0.001) but an equivalent
amount of elastase activity as isolates from controls. The suppression of P. aeruginosa exoenzymes may arrest
progressive lung injury during chronic P. aeruginosa lung infections.
Cystic fibrosis is the most common lethal genetic disorder
of Caucasians (14). Individuals with cystic fibrosis suffer
from chronic infection and progressive destruction of their
airways (15), and once they are colonized by Pseudomonas
aeruginosa there is a relentless decline in pulmonary func-
tion leading to respiratory failure and death (21). During
exacerbations of their respiratory disease, treatment with
antipseudomonal antibiotics frequently leads to clinical im-
provement, which occurs in the absence of a significant or
sustained bacteriological response (5, 25). The replication of
P. aeruginosa in bronchial secretions may not be as impor-
tant as the production of extracellular enzymes, which are
believed to play an important role in the pathogenesis of
disease due to this organism (36). Suppression of these
exoenzymes may limit the progressive lung damage experi-
enced by patients with cystic fibrosis.
Exoenzymes phospholipase C, exotoxin A, the proteases,
and in particular, elastase and exoenzyme S are important
virulence factors for P. aeruginosa lung infections (34).
Aminoglycosides, in subinhibitory concentrations, have
been shown to inhibit the secretion of proteases in vitro (7,
9, 11, 30), and ciprofloxacin has been shown to reduce levels
of proteases and exotoxin A both in vitro and in vivo in the
rat granuloma-pouch model for chronic local P. aeruginosa
infection (7, 11). Suppression of the exoenzymes by beta-
lactams has been much less consistently observed (7, 9, 11).
The study aims were therefore to examine the effects of
subinhibitory concentrations of ciprofloxacin, tobramycin,
and ceftazidime upon the expression of five P. aeruginosa
exoenzymes in vitro and in vivo by using the rat lung model
of P. aeruginosa infection.
* Corresponding author.
MATERIALS AND METHODS
Bacterial strains. Two strains of P. aeruginosa were used
in this study. Strain DG1 secretes large quantities of
exoenzyme S and the proteases but little exotoxin A (35).
The second strain, PAO, produces significant amounts of
exotoxin A, phospholipase C, and the proteases but minimal
exoenzyme S (32). Down-regulation of exoenzyme S and
total protease and elastase expression by sub-MICs of the
antibiotics were examined in DG1. Similar effects for sub-
MICs of the antibiotics upon exotoxin A and phospholipase
C activity were determined with PAO.
Antibiotics. Ciprofloxacin (Miles Pharmaceuticals), a fluo-
roquinolone, tobramycin (Eli Lilly & Co.), an aminoglyco-
side, and ceftazidime (Ayerst), a beta-lactam, were the
antibiotics used for study.
Culture Conditions. (i) Dose responses. Overnight broth
cultures of P. aeruginosa were diluted between 1:20 and 1:
200 in fresh media. To achieve maximal exoenzyme secre-
tion, bacterial dilutions were individualized for each type of
broth media so that the bacterial growth by the end of 24 h
had reached the late-log phase (12, 17, 33) and an A550 of
>1.4. Following dilution, the organisms were then exposed
to 1/5, 1/10, or 1/20 of the MICs of each antibiotic in 10 flask
replicates. An additional 10 flasks served as untreated con-
trols. The antibiotic concentrations were predetermined by
measurement of the MICs by the broth microdilution method
(8). After a 24-h incubation, turbidity was measured at A550,
and the culture supernatants were then collected and stored
at -70°C to await future exoenzyme determination.
Exoenzyme values from treated flasks were adjusted accord-
ing to their relative turbidity with those from control flasks.
(ii) Time series. Because of the importance placed upon
exoenzyme S and elastase in the pathogenesis of P. aerugi-
nosa lung infection, the effect of subinhibitory antibiotic
concentrations on the expression of these two exoenzymes
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was studied longitudinally in vitro. Serial batch cultures of
P. aeruginosa were constantly exposed to 1/10 of the MICs
of the antibiotics for 10 days. There were 10 flask replicates
for each antibiotic treatment and control group. Cultures
were diluted daily 1:10 into either fresh media and antibiotic
(treatment group) or fresh media alone (control group). All
culture turbidities were standardized to an A550 of 1.75
before supernatants were collected on days 0, 3, 5, 7, and 10
and stored at -70°C. MICs were measured before, during,
and after treatments.
Exoenzyme assays. (i) Exotoxin A. ADP-ribosyl transferase
activity was measured in supematants from P. aeruginosa
PAO grown at 32°C in trypticase soy broth which had been
treated with chelex (Bio-Rad Laboratories, Richmond,
Calif.) to remove iron and supplemented with 1% glycerol
and 100 mM monosodium glutamate (TSBDC medium; 4).
An activation step was initiated by the addition of 4 M urea
and 1% dithiothreitol to the culture supematants, which
were then incubated at 25°C for 20 min. Reaction mixtures
consisted of 10 ,ul of the activated supernatant, 25 ,ul of
buffer (50 mM Tris [pH 7.2], 0.1 mM EDTA, 40 mM
dithiothreitol), 25 ,u of wheat germ extract (aminoacyl
transfer factors) as substrate, and 5 ,ul of [14C]NAD (25 ,uCi/
ml; Amersham Corp., Arlington Heights, Ill.). The mixtures
were incubated at 25°C for 30 min, and the reaction was
terminated by 10% trichloroacetic acid (34). The precipitates
were collected by filtration and counted on a scintillation
counter (Beckman LS6800) as counts per minute.
(ii) Exoenzyme S. This exoenzyme was also measured by
ADP-ribosyl transferase activity. However, P. aeruginosa
DG1 was grown at 32°C in M9 mineral salts medium supple-
mented with 5 mM EDTA, 100 mM sodium succinate, 1%
glycerol, and 100 mM monosodium glutamate (S medium;
35). No activation was performed, and the reaction buffer
was 50 mM Tris (pH 7.2)-0.1 mM EDTA-40 mM dithiothrei-
tol (34).
(iii) Phospholipase C. P. aeruginosa PAO was grown in
tryptose minimal medium at 32°C, and 10 mg of decolorizing
carbon was added to 1 ml of culture supernatant to remove
interfering pigment. After centrifugation, 10 ,ul of superna-
tant was added to 90 ,ul of a solution containing 250 mM Tris
buffer (pH 7.2), 60% glycerol, 1.0 ,uM ZnCl2, and 10 mM
p-nitrophenylphosphorylcholine (Sigma Chemical Co., St.
Louis, Mo.) in individual wells of a 96-well microdilution
tray (3). These were incubated at 37°C for 1 h and the A405
read in a Microelisa El 310 autoreader (Bio-Tek Instru-
ments, Inc., Burlington, Vt.).
(iv) Total protease. P. aeruginosa DG1 was grown in brain
heart infusion broth at 37°C, and 0.5 ml of culture superna-
tant was diluted 1:5 in 10 mM Tris, pH 7.5, and added to 7.5
mg of hide powder azure (Sigma) substrate (34). The mixture
was incubated at 37°C for 1 h while being shaken vigorously.
Undissolved substrate was removed by centrifugation (3,000
x g; 10 min), and protease activity was determined by
comparing A595 values of the supernatants to those of a
standard curve prepared by using purified P. aeruginosa
protease (Nagase Biochemicals Ltd.).
(v) Elastase. The method was the same as that for total
protease, except the culture supernatants were diluted 1:3, 5
mg of elastin Congo red (Sigma) was the substrate used,
incubation time was 2 h, and the absorbance read was A495.
Values were compared with those of a standard curve
derived by using purified P. aeruginosa elastase (Nagase).
In vivo treatments. Sixty-eight young adult male Sprague-
Dawley rats were ether anesthetized and inoculated with P.
aeruginosa DG1 enmeshed agar beads via the trachea (6).
After 72 h, the rats were divided into four equal treatment
groups. The antibiotic dosages were chosen to ensure sub-
inhibitory concentrations. The treatments were administered
as single daily intramuscular injections in the following doses
(mg/kg per day): ciprofloxacin, 2 (13); tobramycin, 5 (22); or
ceftazidime, 10 (24). The fourth treatment group was the
untreated controls.
To determine whether tissue antibiotic levels were below
the MIC, an additional 10 rats were studied. These uninfec-
ted animals were divided into three treatment groups, one
for each antibiotic, and the remaining rat served as an
untreated control. Antibiotics were administered as de-
scribed above. After 10 days, the rats were sacrificed one h
after their antibiotic injections, and the lung antibiotic con-
centrations were measured by bioassay (2). Drug levels were
derived from a standard curve prepared by using known
antibiotic concentrations added to untreated rat lung homo-
genate (24). Haemophilus influenzae Rdnov (1) was the
indicator organism for ciprofloxacin and ceftazidime deter-
minations, and Escherichia coli K-12 SA1306 was the indi-
cator for tobramycin.
Following 10 days of subinhibitory therapy, the animals
were sacrificed. The lungs of five animals from each group
were homogenized for quantitative bacteriology by serial
dilution (6). Subculture of these rat lung isolates onto
TSBDC and M9 minimal medium agar plates enabled five
discrete colonies from each rat lung to be grown in the
appropriate broth for exoenzyme assays and MIC determi-
nations. The lungs from the remaining 12 animals in each
group were Formalin fixed for hematoxylin and eosin tissue
staining and histological examination (28).
Statistics. Statistical calculations were by Minitab (Minitab
Manual, 1985). Comparison of outcomes within the dose-
response experiments and the in vivo rat lung model was by
one-way analysis of variance. When the distribution of the
data was not normal, the Kruskal-Wallis test was performed.
Data from the time series experiments for exoenzyme S and
elastase were first transformed into square root values and
logarithms, respectively, and then evaluated by a two-way
analysis of variance for repeated-measures design (16).
RESULTS
The effects upon exoenzyme expression by P. aeruginosa
following 24-h growth in broth and exposure to subinhibitory
concentrations of antibiotics in vitro are. shown in Table 1.
Ciprofloxacin, sometimes at levels only 1/20 of the MIC, was
capable of significantly reducing exoenzyme values. Exotox-
in A secretion was reduced to 34% (one-way analysis of
variance; F3,36 = 7.6; P < 0.001); exoenzyme S to 25% (F3,36
= 96.4; P < 0.001); phospholipase C was undetectable; total
protease activity was as low as 2% (Kruskal-Wallis; H3 =
29.34; P < 0.001); and elastase activity even lower at 1%
(F3,36 = 10.5; P < 0.001). Tobranmycin was also capable of
decreasing exoenzymes in vitro, but the magnitude of this
reduction was not as great as that for the other two antibi-
otics. In addition, only elastase activity was diminished
when the tobramycin concentration was as low as 1/20 of the
MIC. Modest but significant reductions in exotoxin A (86%;
F3,36 = 6.4; P < 0.01) and exoenzyme S (80o; F3,36 = 4.05;
P < 0.05) activity were detected. As with ciprofloxacin,
phospholipase C could not be measured when the antibiotic
concentration was 1/10 of the MIC. Total proteases were
33% of the control values (H3 = 8.25; P < 0.05), and elastase
was 12% (H3 = 16.74; P < 0.001). Like ciprofloxacin,
ceftazidime was able to inhibit exoenzyme function, fre-
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TABLE 1. In vitro dose-response values of P. aeruginosa exoenzymes for sub-MICs of antibiotics
Exoenzyme St Antibiotic concn Mean ± SEM (% of control)(uitofenzviyme Strain (xllolMconc(unit of activity) rain (xMIC) Ciprofloxacin Tobramycin Ceftazidime
Exotoxin A (cpm) PAO 0.2 1,053 ± 212" (34) 3,703 ± 110 (90) 945 ± 53a (57)
0.1 1,346 ± 265a (43) 3,534 ± 120a (86) 912 ± 41" (55)
0.05 2,764 ± 412 (88) 3,700 ± 79 (90) 1,464 ± 122 (88)
Control 3,128 ± 519 4,112 ± 72 1,671 ± 42
Exoenzyme S (cpm) DG1 0.2 7,765 ± 1035a (25) 29,141 ± 2,109a (80) 17,706 ± 3,406a (56)
0.1 10,835 ± 1044" (35) 29,311 ± 1,466" (80) 16,862 ± 2,362a (54)
0.05 10,771 ± 1295" (35) 32,473 ± 1,936 (89) 16,729 ± 1,729" (53)
Control 30,716 ± 1043 36,561 ± 741 31,452 ± 1,734
Phospholipase C (A405) PAO 0.2 NDa"b NDa 0.15 ± 0.01a (12)
0.1 NDa NDa 0.64 ± 0.05a (50)
0.05 0.14 ± 0.02 (74) 0.64 ± 0.07" (65) 0.69 ± 0.04" (55)
Control 0.19 ± 0.03 0.99 ± 0.05 1.26 ± 0.08
Total protease (,Ug/ml) DG1 0.2 1.8 ± 0.9C (2) 10.5 ± 1.3C (33) 0.5 ± 0.2c (2)
0.1 10.1 ± 2.2c (14) 11.5 ± 1.6 (36) 9.5 ± 3.2c (30)
0.05 30.8 ± 8.7c (43) 11.9 ± 1.7 (37) 33.3 ± 5.5 (104)
Control 72.3 ± 8.4 31.0 ± 11.6 32.1 ± 4.8
Elastase (ALg/ml) DG1 0.2 0.069 ± 0.005a (1) 0.927 ± 0.200c (20) 0.069 ± 0.010C (1)
0.1 0.103 ± 0.013" (2) 0.737 ± 0.132c (16) 0.129 ± 0.016c ((2)
0.05 0.921 ± 0.232a (16) 0.539 ± 0.121c (12) 1.253 ± 0.359c (24)
Control 5.713 + 1.562 4.525 ± 1.002 5.075 ± 1.236
a Significant difference from control mean (P < 0.05) by one-way analysis of variance.
b ND, No activity detected.
c Significant difference from control mean (P < 0.05) by Kruskal-Wallis test.
quently at concentrations of 1/20 of the MIC. Exotoxin A
expression was 55% of the values measured from untreated
controls (F3 36= 27.1; P < 0.001); exoenzyme S, 53% (F3,36
= 7.2; P < 0.001); phospholipase C, 12% (F3,36 = 67.4; P <
0.001); total protease, 2% (H3 = 29.02; P < 0.001); and
elastase, 1% (H3 = 31.38; P < 0.001).
The effects upon the expression of exoenzyme S and
elastase when P. aeruginosa DG1 was exposed for 10 days
to a constant subinhibitory concentration (1/10 of MIC) ofan
antibiotic are illustrated in Fig. 1 and 2, respectively. The
base-line exoenzyme measurements from the treatment
groups did not differ from one another (exoenzyme S: F3,36
= 1.39 [P > 0.05]; elastase: F3,36 = 0.83 [P > 0.05]), and thus
two-way analysis of variance of the repeated-measures de-
sign for the four treatments over the four times (days 3, 5, 7,
and 10) was employed to analyze the data from the time
curves. The results for exoenzyme S were as follows. (i) A
significant effect for time (F3,117 = 14.8; P < 0.001), re-
flecting the tendency for the counts to vary with time for
three of the treatments, was shown, as was (ii) a highly
significant (F3,36 = 132; P < 0.001) effect for antibiotics,indicating the mean exoenzyme S counts per minute for
these groups differed from those for controls (mean cpm for
ciprofloxacin-treated flasks = 20,978; mean cpm for tobra-
mycin-treated flasks = 21,417; mean cpm for ceftazidime-
treated flasks = 16,947; mean cpm for control flasks =
38,535). (iii) A significant time-by-treatment interaction
(Fg,144= 7.69; P < 0.001), reflecting that the time-response
curves for all treatments varied, was also shown. The results
of a similar analysis for elastase were as follows. (i) A highly
significant effect (F3,36 = 20.73; P < 0.001) for ciprofloxacin
and tobramycin treatments when compared with that for
controls (mean elastase value [p.g/ml] for ciprofloxacin-
treated flasks, 5.9; for tobramycin-treated flasks, 4.4; for
ceftazidime-treated flasks, 7.7; for control flasks, 11.7) was
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FIG. 1. Effect of 10-day subinhibitory antibiotic concentrations
(1/10 of MIC) upon exoenzyme S expression in vitro by P. aerugi-
nosa DG1.
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FIG. 2. Effect of 10-day subinhibitory antibiotic concentrations
(1/10 of MIC) upon elastase expression in vitro by P. aeruginosa
DG1.
shown, as was (ii) a significant time-by-treatment interaction
(F9,144 = 5.90; P < 0.001), reflecting that all curves varied
over time.
The MIC of ciprofloxacin before the time series study was
0.015 pug/ml. However, by day 3 the MIC had increased
32-fold to 0.5 ,ug/ml and remained at this value throughout
the remaining 7 days of the experiment. When the ciproflox-
acin was discontinued and the MIC was determined 4 days
later, it had decreased to an intermediate value of 0.125 jxg/
ml. The MICs for tobramycin and ceftazidime remained
unchanged throughout the course of the experiment at 0.25
and 1.0 ,ug/ml, respectively.
The quantitative bacterial counts from each of the five
homogenized rat lungs in each group revealed no differences
in the numbers ofCFU present between animals treated with
antibiotics and control animals (F3,13 = 0.6; P > 0.05). Mean
numbers (± standard errors of the mean) of bacteria x 10-6
per lung for each group were as follows: ciprofloxacin, 3.80
±1.02; tobramycin, 2.40 + 0.75; ceftazidime, 3.25 0.25;
and controls, 2.60 + 1.20. The absence of bacterial killing in
antibiotic-treated animals was predictable based on the
sub-MICs of the antibiotics administered. Further, bioassay
of antibiotic levels in homogenized lung tissue demonstrated
levels of less than one-fifth the MIC of each antibiotic per
homogenate.
Selected examples of whole rat lung sections are shown in
Fig. 3, which illustrates the differences in degree of histo-
logical injury between treated and control animals. Minimal
consolidation was present in the lungs of ciprofloxacin- and
tobramycin-treated rats (Fig. 3A and B). The histological
damage in ceftazidime-treated lungs was more extensive
(Fig. 3C), but the severest inflammation was seen in the
control lungs (Fig. 3D). The pathological index for each lung
was determined by the following formula: pathological index
= (estimated area of lung consolidation/total lung area) x
100, and represented the percentage of rat lung injured
following infection with P. aeruginosa (28). The mean patho-
logical indices (and their ranges) for ciprofloxacin-, tobramy-
cin-, and ceftazidime-treated lungs from the 12 rats in each
group were 2.1 (0.0 to 6.9), 4.9 (0.0 to 9.6), and 14.5 (7.2 to
20), respectively, and these values were significantly less
than the index of 31.6 (10.4 to 53.0) for the untreated control
lungs (F3,36 = 31.23; P < 0.001). In addition, ceftazidime-
treated rats sustained significantly greater histological lung
damage than those given either ciprofloxacin or tobramycin
(F2,27 = 11.83; P < 0.001).
The mean exoenzyme values for the rat lung P. aerugi-
nosa DG1 isolates are outlined in Fig. 4. A major finding was
that the mean values for exoenzyme S activity from the
antibiotic-treated lung isolates (ciprofloxacin group, 21,240
cpm; tobramycin group, 20,107 cpm; ceftazidime group,
23,295 cpm) were significantly less than that measured from
the isolates of untreated lungs (control group, 31,998 cpm)
(F3,124 = 22.07; P < 0.001). In addition, the mean elastase
expression measured from ciprofloxacin (3.79 ,ug/ml)- and
tobramycin (4.11 ,ug/ml)-treated lung isolates was signifi-
cantly different from that of controls (4.87 ,tgIml) (F3,74 =
12.29; P < 0.001). However, isolates treated in vivo with
ceftazidime expressed an equivalent degree of elastase ac-
tivity (4.72 pugIml) as isolates of controls.
There was no documented increase in the MICs of cipro-
floxacin, tobramycin, or ceftazidime by any of the isolates at
the end of the rat lung experiment.
DISCUSSION
The pathogenesis of progressive lung injury during chronic
P. aeruginosa infection is multifactorial (20). However, P.
aeruginosa exoenzymes are important virulence factors,
either by their direct action or by the immune response of the
host to these exoproducts (23). The results of this study
indicate that P. aeruginosa exoenzyme expression can be
down-regulated, both in vitro and in vivo, by antibiotics at
concentrations which do not inhibit bacterial growth. In
addition, even in the presence of multiplying bacteria, sub-
inhibitory concentrations of the antibiotics protected lungs
from significant histological injury.
The three antibiotics studied, ciprofloxacin, tobramycin,
and ceftazidime, were all able to suppress the expression of
the five exoenzymes in vitro when present at sub-MICs. This
effect was most consistent for ciprofloxacin, and the prote-
ases were the most susceptible of the exoenzymes to sup-
pression after 24-h growth in a broth culture. These results
support and extend the observations of other workers who
have reported the inhibition of exoenzyme function in the
presence of antibiotics. Protease secretion, including
elastase, has been suppressed in vitro by sub-MICs of
ciprofloxacin (7), gentamicin (30), tobramycin (11, 30), azlo-
cillin (11), ceftazidime (11), and tetracycline (27). Exotoxin
A production in resistant isolates of P. aeruginosa has also
been inhibited in vitro by ciprofloxacin (7). However, to our
knowledge this is the first time either exoenzyme S or
phospholipase C has been reported to be suppressed by
subinhibitory antibiotic concentrations. These two
exoenzymes were suppressed in vitro by all three antibiotics
and at levels as low as 1/20 of the MIC. The demonstration
of exoenzymne S suppression is particularly significant as this
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FIG. 3. Selected examples of hematoxylin-and-eosin-stained whole lung sections from rats infected intratracheally with P. aeruginosa
DG1 embedded agar beads and treated for 10 days by subinhibitory doses of ciprofloxacin (A), tobramycin (B), and ceftazidime (C). (D)
Untreated controls.
exoenzyme is believed to be a major virulence determinant
of chronic P. aeruginosa lung infection (19, 20, 34, 35).
The exoenzymes exoenzyme S and elastase are the two
dominant exoproducts secreted by clinical isolates from
patients with P. aeruginosa pneumonia (34). The in vitro
time series experiment in which P. aeruginosa DG1 was
exposed to a constant 1/10 MIC of antibiotic for 10 days
again demonstrated that ciprofloxacin, tobramycin, and cef-
tazidime were able to suppress exoenzyme S function and
that this suppression was maintained during the course of the
experiment. The down-regulation of elastase expression
during the same experiment occurred with ciprofloxacin and
tobramycin but not with ceftazidime. The degree of suppres-
sion of elastase function was not as complete as it was in the
dose-response experiments. However, in the latter, the
dilution of organisms from the starter culture was 1:200. To
ensure a continued high level of growth in the serial batch
cultures from both antibiotic-treated and untreated flasks
during the time series experiment, bacterial dilutions of 1:10
were required. These lesser dilutions may have introduced
an inoculum effect which would have been significant for the
beta-lactam antibiotic ceftazidime (31), raising the MIC for
the organism to this antibiotic, and thus the expected 1/
10 MIC may have been very much lower. If this was so, then
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FIG. 4. Mean exoenzyme expression by rat lung P. aeruginosa
DG1 isolates following 10-day treatments with subinhibitory doses
of antibiotics expressed as a percentage of the exoenzyme values
from the untreated rat lung isolates. I, standard error of the mean; *,
a significant difference (P < 0.05) from the control mean by one-way
analysis of variance.
the ceftazidime level may have been too low to inhibit
elastase. By way of contrast, the dilutions for exoenzyme S
dose-response studies were 1:20, so there was little differ-
ence in the inocula used for these two experiments and their
results were correspondingly in good agreement.
During the longitudinal in vitro experiments, relative
resistance to the bactericidal effects of ciprofloxacin devel-
oped quickly. There was a 32-fold increase in the MIC of
ciprofloxacin by day 3 of the experiment, but this remained
stable and within the clinically susceptible range of less than
2.0 ,ug/ml (26). Similar observations have been made in vitro
and in patients during treatment for P. aeruginosa infections
(18, 26). In spite of the increase in MIC of ciprofloxacin, the
phenotypic effects of exoenzyme suppression were main-
tained at levels which would have been as low as 1/320 of the
MIC. No such changes in the MIC were detected for
tobramycin and ceftazidime. The MICs of ceftazidime and
tobramycin were also tested in washed cells taken directly
from the broth culture. The results were identical to those
obtained by subculturing the organisms first on a TSBDC
plate (data not shown).
Ciprofloxacin, tobramycin, and ceftazidime treatment of
rats chronically infected with P. aeruginosa protected the
animals from lung injury without altering bacterial numbers.
The protective effect was greatest for ciprofloxacin and
tobramycin. Ceftazidime gave only partial protection. Rat
lung P. aeruginosa isolates from ciprofloxacin- and tobra-
mycin-treated animals demonstrated significantly less
exoenzyme S activity and elastase activity than controls.
However, isolates from ceftazidime-treated lungs produced
less exoenzyme S than control isolates but an equivalent
degree of elastase activity. There have been few studies
which have examined the effects of subinhibitory antibiotics
in vivo. Subinhibitory concentrations of gentamicin and
tobramycin were recently shown to protect the epithelium of
hamster tracheal cultures from damage during infection by
P. aeruginosa (9). In addition, these antibiotics also inhib-
ited the production of exotoxin A and elastase by the
infecting organisms. P. aeruginosa-infected tracheal cul-
tures were not protected by the beta-lactams, carbenicillin,
or ceftazidime, and the organisms still produced high levels
of exotoxin A and elastase. The subinhibitory concentra-
tions of aminoglycosides may have protected the epithelium
from damage by reducing the secretion of bacterial
exoenzymes. In similar fashion, reduction in elastase or
exoenzyme S or both by ciprofloxacin, tobramycin, and
ceftazidime may have been important in the prevention of
histological damage to the antibiotic-treated rat lungs. The
finding that these were the exoenzymes suppressed in the
bacterial isolates from the lungs with least damage adds
further indirect support to the hypothesis that they are the
major exoenzymes responsible for the pathogenesis of P.
aeruginosa lung infection. The intermediate level of protec-
tion afforded by ceftazidime was of interest, as this antibiotic
suppressed only exoenzyme S function and not that of
elastase in the lung isolates. This also suggests elastase is an
important virulence factor in chronic P. aeruginosa lung
infection.
The reductions in the concentrations of the exoenzymes
from the rat lung model were relatively modest when com-
pared with the degree of protection from histological injury.
It is possible that the subculturing of the rat lung isolates
required for exoenzyme measurements enabled the bacteria
to revert to their original phenotype in the absence of the
antibiotic. Attempts to measure exoenzymes directly from
bronchoalveolar fluid obtained from the rats were unsuc-
cessful (data not shown). Direct exoenzyme antigen assays
from lung tissue could have overcome this particular prob-
lem, but they would not have yielded information about
exoenzyme function. Measurements of enzymatic activity in
the rat lungs were also not undertaken because of reported
interference with the functional assays (19). However, 24 h
following the withdrawal of ceftazidime from antibiotic-
treated flasks in the time series experiment, exoenzyme
expression remained suppressed in the culture supernatants.
During the same experiment, exoenzymes from ciproflox-
acin- and tobramycin-treated flasks remained inhibited for
up to 4 days and four passages in antibiotic-free media (data
not shown). This suggests that at least ciprofloxacin and
tobramycin induced a transient change in phenotype. It also
supports the use of in vitro methods to estimate the
exoenzyme expression by P. aeruginosa isolates in vivo.
Nevertheless, what must also be borne in mind is that the
protective effect shown by the antibiotics in vivo may be
related to factors other than exoenzymes. It is known, for
example, that subinhibitory concentrations of tobramycin
and ceftazidime inhibit the adherence of mucoid strains to
hamster tracheal epithelium (10) and tracheobronchial mu-
cus (29), respectively. While this factor would not be ex-
pected to operate in these experiments because nonmucoid
strains were employed, it does underscore the complexity of
the interactions between the microorganism and sub-MICs
of antibiotics.
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